期刊文献+

英夫利西单抗治疗关节病型疾病输注流程及护理体会

下载PDF
导出
摘要 目的探讨英夫利西单抗治疗关节病型疾病的输注流程以及护理体会。方法选择2013年8月至2014年6月于医院治疗关节病型疾病患者15例,对15例患者采取静脉注射英夫利西单抗进行治疗,注射次数3~5次。严格按照患者的病情控制输注时间.并且在治疗前及治疗后2个月对患者的生命体征进行观察,向患者或者患者家人咨询治疗效果。结果关节病型疾病患者治疗2个月后,心理及生理都有较大改善,社会功能及健康自我意识等生命总体质量与治疗前相比都有很大提高。15例患者在进行治疗的过程中并没有发生严重不良反应,对于一些轻微不良反应给予减缓输液速度的措施后.不良反应消失。结论英夫利西单抗治疗关节病型疾病能有效改善患者病情,在治疗过程中进行适"-3护理能有效预防治疗过程中出现的不良反应.提高患者的生活质量。 Objective On infliximab infusion joint disease process and Nursing.Methods August 2013-June 2014 in our hospital 15 cases of patients with joint disease, 15 patients taking intravenous infliximab treatment,injections of 3-5 times. In strict accordance with the patient's disease control infusion time,and before treatment,and after 2 months of treatment the patient's vital signs were observed in patients or family members of patients to treatment advice.Results Joint disease patients two months ,either mental or physical has has greatly improved compared to before the overall quality of life and treatment greatly improved,social function and health of self-awareness.And no serious adverse reactions in 15 patients during the course of therapy,for some minor measures to mitigate adverse effects of the infusion rate after administration,adverse reactions disappear.Conclusions Infliximab joint disease can effectively improve the patient's condition,appropriate care in the course of treatment can effectively prevent ad- verse reactions during infliximab appears.Improve the patient's living standards,improve the quality of life of patients.
出处 《中国药业》 CAS 2015年第B12期295-296,共2页 China Pharmaceuticals
关键词 英夫利西单抗治疗关节病型 输注流程 护理体会 infliximab joint disease infusin process nursing experience
  • 相关文献

参考文献6

二级参考文献29

  • 1邓小虎,黄烽.英夫利西单抗治疗炎性关节病的研究进展[J].中国药物应用与监测,2006,3(6):10-14. 被引量:17
  • 2侯勇,张奉春,黄烽,吴东海,鲍春德,倪立青,姚晨.Infliximab治疗类风湿关节炎的随机双盲平行多中心临床试验[J].中华风湿病学杂志,2006,10(11):658-663. 被引量:34
  • 3王莉莎,黄烽,张江林,邓小虎,张亚美,张莉芸,郭军华.肿瘤坏死因子拮抗剂在治疗强直性脊柱炎中的安全性分析[J].中国新药杂志,2007,16(7):556-561. 被引量:24
  • 4CHOY EH, PANAYI GS. Cytokine pathways and joint inflammation in rheumatoid arthritis[J]. N Engl J Med, 2001, 344(12): 907-916.
  • 5RIGBY WF. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive benavior? [J]. Nat Clin Pract Rheumatol, 2007, 3(2): 227-233.
  • 6SCALLON B, CAI A, SOLOWSKI N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists[J]. J Pharmacol Exp Ther, 2002, 301 (2): 418-426.
  • 7St CLAIR EW, van DER HEIJDE DM, SMOLEN JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial[J]. Arthritis Rheum, 2004, 50( 11 ) : 3432-3443.
  • 8GOEKOOP-RUITERMAN YP, de VRIES-BOUWSTRA JK, ALLAART CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study) : a randomized, controlled trial [J]. Arthritis Rheum, 2005, 52(11 ) : 3381-3390.
  • 9MAINI RN, BREEDVELD FC, KALDEN JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate[J]. Arthritis Rheum, 2004, 50(4) : 1051-1065.
  • 10van DER BIJL AE, GOEKOOP-RUITERMAN YP, de VRIESBOUWSTRA JK, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis[J]. Arthritis Rheum, 2007, 56(7): 2129-2134.

共引文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部